Standout Papers

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia 2002 2026 2010 2018 1.5k
  1. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia (2002)
    Hagop Kantarjian, Charles L. Sawyers et al. New England Journal of Medicine
  2. Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer (2013)
    Helmut Oettle, P. Neuhaus et al. JAMA
  3. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (2010)
    Giuseppe Saglio, Dong‐Wook Kim et al. New England Journal of Medicine
  4. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (2010)
    Hagop M. Kantarjian, Neil P. Shah et al. New England Journal of Medicine
  5. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL (2006)
    Hagop M. Kantarjian, Francis J. Giles et al. New England Journal of Medicine
  6. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia (2003)
    Timothy P. Hughes, Jaspal Kaeda et al. New England Journal of Medicine
  7. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet (2009)
    Michele Baccarani, Jörge E. Cortes et al. Journal of Clinical Oncology
  8. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders (2010)
    Thomas Ernst, Andrew Chase et al. Nature Genetics
  9. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017)
    Andreas Hochhaus, Richard A. Larson et al. New England Journal of Medicine
  10. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy (2002)
    Andreas Hochhaus, Sebastian Kreil et al. Leukemia
  11. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (2009)
    Andreas Hochhaus, S G O'Brien et al. Leukemia
  12. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial (2016)
    Jörge E. Cortes, Giuseppe Saglio et al. Journal of Clinical Oncology
  13. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial (2016)
    Andreas Hochhaus, Giuseppe Saglio et al. Leukemia
  14. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance (2007)
    Hagop M. Kantarjian, Francis J. Giles et al. Blood
  15. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) (2011)
    Hagop M. Kantarjian, Neil P. Shah et al. Blood
  16. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia (2016)
    Juan Luis Steegmann, Michele Baccarani et al. Leukemia
  17. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial (2017)
    Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 15 from Science/Nature 71 standout
Sub-graph 1 of 19

Citing Papers

Pancreatic cancer
2025 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel

Works of Andreas Hochhaus being referenced

Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
2013 Standout
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
2011 Standout

Author Peers

Author Last Decade Papers Cites
Andreas Hochhaus 29429 23691 15371 819 39.2k
Moshe Talpaz 28654 22419 12929 765 44.0k
Michele Baccarani 19737 14203 7958 704 28.3k
John M. Goldman 21809 13997 8428 486 29.2k
Brian Druker 29898 21325 13369 597 54.0k
Srđan Verstovšek 18254 18322 8353 1.1k 29.2k
Francis J. Giles 20046 15414 6250 778 41.0k
Giuseppe Saglio 18032 13149 6880 643 24.4k
Susan O’Brien 20888 16969 5501 837 35.7k
Ayalew Tefferi 34157 37379 15562 1.1k 53.3k
Guillermo Garcia‐Manero 29771 14343 4360 1.5k 42.9k

All Works

Loading papers...

Rankless by CCL
2026